Mode
Text Size
Log in / Sign up

Enteral nutrition in neurocritical patients shows feeding intolerance rates between 46.38% and 62.0%Sedation medications may increase feeding problems in critically ill patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that enteral nutrition in neurocritical patients is associated with feeding intolerance rates of 46.38-62.0%.

This systematic review explores enteral nutrition strategies for neurocritical patients who require sedation and analgesia. The scope includes evaluating feeding intolerance (FI) as a primary outcome, alongside secondary outcomes such as gastric residual volume, abdominal distension, vomiting, and the ability to meet enteral nutrition targets within 72 hours.

The synthesis indicates that the rate of feeding intolerance in these patients ranges from 46.38% to 62.0%. The review notes that the use of opioids and benzodiazepines is associated with impaired gastrointestinal motility and barrier function, which are factors contributing to increased risks of feeding intolerance.

While the review provides theoretical and practical references for managing nutritional support aligned with 2023-2024 ESPEN/ASPEN guidelines, it does not report primary trial data. The findings are intended to help clinicians develop individualized nutrition plans by clarifying pathophysiology and risk factors. Clinical application is limited by the lack of reported primary trial data in the review's synthesis.

How this fits prior evidence

This systematic review addresses a gap in managing nutritional support for neurocritical patients. It specifically notes that opioids and benzodiazepines contribute to impaired gastrointestinal motility, which may increase feeding intolerance risk. This finding relates to prior coverage regarding opioid use; while other evidence confirms that opioids provide clinically important pain relief for short durations, this study highlights the specific gastrointestinal complications associated with their use in the neurocritical setting.

When a patient is in a neurocritical care unit, they often need heavy sedation and pain relief. These medications, specifically opioids and benzodiazepines, are vital for keeping patients stable. However, these drugs can also slow down the digestive system and weaken its protective barrier. This makes it harder for the body to process nutrients properly.

Research shows that between 46.38% and 62.0% of these patients experience feeding intolerance. This means their bodies struggle to handle the nutrition they need while under sedation. The study highlights how certain medications directly contribute to this risk, making it harder for medical teams to meet nutritional goals during the first 72 hours of care.

While the review provides a roadmap for better management and individualized plans, it is important to note that these findings are based on existing literature rather than new trial data. Doctors use these insights to help create safer ways to feed patients while they are under heavy medication.

What this means for you:
Opioids and benzodiazepines can cause feeding issues in about half of neurocritical patients during sedation.

Common questions

What is feeding intolerance in these patients?

Feeding intolerance means a patient's body cannot properly handle the nutrition they are receiving. In this study, between 46.38% and 62.0% of neurocritical patients experienced this issue while undergoing sedation and analgesia.

Why do some medications cause feeding problems?

Certain medications used for pain and sedation, specifically opioids and benzodiazepines, can impair the movement of the digestive system and weaken its barrier function. This makes it harder for patients to tolerate nutrition while they are in a critical care unit.

Who is affected by these findings?

These findings specifically concern neurocritical patients who require sedation and analgesia. The research focuses on how their bodies respond to treatment during the early stages of their hospital stay.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
In the Neurocritical Care Unit (NICU), deep sedation and analgesia are essential for managing critically ill patients to control intracranial pressure and reduce brain stress. However, these drugs—particularly opioids and benzodiazepines—significantly impair gastrointestinal motility and barrier function, increasing the risk of feeding intolerance (FI) to 46.38–62.0% in this population (1). FI manifests as elevated gastric residual volume, abdominal distension, vomiting, or failure to meet enteral nutrition targets within 72 h (2), and is associated with higher infection rates, prolonged hospital stay, increased medical costs, and worse neurological and overall prognosis (3). Therefore, clarifying the pathophysiological mechanisms, risk factors, assessment methods, and management strategies of FI in the context of sedation and analgesia is vital for developing standardized, individualized nutritional support plans for neurocritical patients. This review systematically elaborates the “neuro-sedation-gut” triad mechanism, stratifies population-specific risk factors graded by the GRADE system, integrates precise multimodal assessment tools, and proposes an algorithmic management pathway aligned with 2023–2024 ESPEN/ASPEN guidelines, to provide targeted theoretical and practical references for neurocritical care practice.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.